Recruiting NCT05540262
Edaravone in the Treatment of Optic Neuritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Edaravone.
- Who it may be relevant to
- Registry conditions: Optic Neuritis. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Interventions
- Drug Edaravone
Edaravone injection 30mg three times a day
Primary outcome measures
- Best-corrected visual acuity [Time frame: 18 months]
Secondary outcome measures (2)
- Ganglion cell-inner plexiform layer [Time frame: 18 months]
- Peripapillary retinal nerve fiber layer [Time frame: 18 months]
Eligibility criteria
Inclusion criteria
- Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
- Patients with a first episode of optic neuritis in either eye
- First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
Exclusion criteria
- Myopia over 6 diopters
- Refractive media opacity affecting assessment of retinal layers and/or visual acuity
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Yi Du — Nanning
Identifiers
NCT: NCT05540262 · GXEDAON1.0